SeaStar Medical Holding Corp

NASDAQ:ICUUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

SeaStar Medical Holding Corporation is a commercial-stage medical technology company. The Company is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The Company's technologies rely on science to provide life-saving solutions to critically ill patients. The Company develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company uses its Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.

Contact Information

Headquarters

3513 Brighton Blvd, Suite 410DENVER, CO, United States 80216

Phone

813-362-6488

Fax

302-655-5049

Executives

Independent Chairman of the Board

Richard Barnett

Chief Executive Officer, Director

Eric Schlorff

Chief Financial Officer

David Green

Vice President - Finance

Caryl Baron

Chief Medical Officer

Kevin Chung